S demonstrated promising antitumor activity. A randomized phase II study of
Chemexpress S demonstrated promising antitumor activity. A randomized phase II study of panitumumab, erlotinib, and GEM in APC showed a trend in OS advantage when compared with GEM plus�AlphaMed PressTheOncologistCMEBiological Therapy…